The Democratic Republic of the Congo is grappling with an Ebola outbreak caused by the Bundibugyo virus strain—a rare variant that has sickened more than 500 people and claimed over 130 lives as of May 20, prompting the World Health Organization to declare a public health emergency of international concern. Yet despite alarming headlines and travel restrictions, the risk to people outside the affected region remains extremely low, according to Michele Barry, director of the Stanford Center for Innovation in Global Health and an expert who has responded to Ebola outbreaks in Uganda and Liberia.
The distinction matters because understanding how Ebola actually spreads—and how this particular strain behaves—separates real risk from pandemic panic. Ebola is far less contagious than COVID-19 or measles. While a tiny exposure to the virus can trigger a potentially fatal infection, transmission requires direct contact with bodily fluids, broken skin, or unprotected mucous membranes. It does not spread through the air like respiratory viruses do. Healthcare workers face greater risk when medical procedures create aerosol particles, and handling the dead without proper protective equipment remains the strongest transmission risk factor. This is why the disease tends to remain localized rather than igniting global outbreaks.
What makes this outbreak particularly challenging, however, is the virus itself. Bundibugyo is the rarest of the six known Ebola species and has caused only two previous outbreaks before this one. Many standard diagnostic tests cannot detect Bundibugyo, which is precisely why this epidemic spread undetected for weeks before officials declared it on May 15. The virus also presents differently than more familiar Ebola strains: non-bloody diarrhea and headache appear as first symptoms more than 80 percent of the time, while the hemorrhagic symptoms associated with Ebola—bleeding—occur as an initial symptom only about 25 percent of the time. This atypical presentation likely delayed recognition and containment efforts.
Another complication concerns medical tools. Excellent Ebola vaccines exist with over 90 percent efficacy rates, but they target the Ebola-Zaire strain, not Bundibugyo. The same limitation applies to therapeutic monoclonal antibodies that have proven effective against other Ebola forms. Health authorities in the DRC and neighboring countries are therefore responding without the pharmaceutical advantages that previous outbreak responses have enjoyed.
Yet Barry emphasizes that a coordinated global response remains vital—not to prevent a pandemic, which she considers extremely unlikely, but to support affected nations in containing the outbreak and saving lives. "While the risk of a pandemic is very low given the way the virus spreads, the impact in the DRC and nearby countries could be devastating," she said. She advocates for scientifically grounded quarantine and travel policies carefully coordinated between nations, acknowledging that viruses respect no borders even if transmission patterns are localized.
The path forward requires balancing legitimate international concern with proportionate action: taking the outbreak seriously in the DRC and neighboring countries while avoiding the overreach that can itself cause harm. It is a distinction that separates sound public health from fear-driven policy.